BeyondSpring, Cerus leads healthcare gainers; Flora Growth, Arcturus Therapeutics among major losers
- BySeeking Alpha-
BeyondSpring BYSI +151%, Cerus CERS +21%, Flora Growth (FLGC) -25%, Arcturus Therapeutics (ARCT) -18%
Symbol | Exchange | Currency |
|---|
BeyondSpring BYSI +151%, Cerus CERS +21%, Flora Growth (FLGC) -25%, Arcturus Therapeutics (ARCT) -18%
Cerus announces the appointment of Ann Lucena to the company's board of directors. Lucena is the chief executive officer of San Ramon Regional Medical Center.Prior to her role...
Cerus Corporation (NASDAQ: CERS) reported second-quarter sales of $37.8 million, +41% Y/Y in line with the consensus.Product revenue reached $31.5 million, compared to $21.5...
This week was all about the stimulus deal, so, since we still don’t have one, it makes complete sense that the market would move lower over these five days. It’s...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Sell | Buy | Buy | Strong Buy |
| Technical Indicators | Sell | Neutral | Strong Buy | Strong Sell | Neutral |
| Summary | Neutral | Neutral | Strong Buy | Neutral | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 149.03 | 149.44 | 146.37 | +0.91 | +0.61% | 81.46M | NASDAQ | |||
| 373.92 | 377.55 | 367.67 | -2.61 | -0.69% | 17.77M | NASDAQ | |||
| 2,888.60 | 2,889.00 | 2,826.90 | +37.7 | +1.32% | 1.19M | NASDAQ | |||
| 54.71 | 55.22 | 54.41 | +0.10 | +0.18% | 440.03K | NYSE | |||
| 223.41 | 223.67 | 219.66 | +0.99 | +0.45% | 16.39M | NASDAQ | |||
| 98.24 | 98.53 | 96.99 | +2.04 | +2.12% | 11.57M | NYSE | |||
| 32.13 | 32.72 | 24.45 | +8.810 | +37.78% | 48.89M | NYSE | |||
| 102.16 | 102.47 | 100.69 | +1.78 | +1.77% | 8.09M | NYSE | |||
| 86.99 | 87.27 | 86.30 | -0.02 | -0.02% | 97.42K | OTC Markets | |||
| 157.86 | 158.03 | 153.92 | -2.29 | -1.43% | 31.65M | NYSE | |||
| 44.77 | 45.37 | 44.47 | +0.06 | +0.13% | 24.84M | NYSE | |||
| 7.26 | 7.30 | 6.94 | +0.400 | +5.83% | 11.77M | NYSE | |||
| 137.20 | 137.80 | 135.67 | +0.98 | +0.72% | 3.25M | NYSE | |||
| 324.08 | 324.47 | 313.29 | +4.83 | +1.51% | 4.16M | NYSE | |||
| 11.61 | 11.66 | 11.57 | -0.09 | -0.77% | 5.17M | NASDAQ |
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.